Invest

  • Ground-floor access
  • $6 million raise
  • Physician-supervised AI
  • Seasoned leadership team
▶ Watch the investor video View the investor deck → Raising $6M · Rule 506(c) · accredited investors only

What Tachyra does

With Tachyra, the world's smartest physician is your physician. Our AI-assisted clinical decision support reviews each patient's full history, medications, and lab trends before the visit, so the physician walks in prepared. The physician makes every decision.

Illustration with a fictional patient

Investor video

Meet Tachyra in a few minutes

Founder Barry Michaels introduces Tachyra: the problem of missed diagnoses and medication harm, how physician-supervised AI helps, and the seed round now forming.

The video starts without sound. Tap the speaker icon to listen. Not playing? Watch it on Vimeo.

Why now

A second look at every patient, built into the visit

795,000

Americans die or are permanently disabled each year from diagnostic error.

Newman-Toker et al., BMJ Quality & Safety, 2024

62.5% → 85.6%

Diagnostic accuracy of individual physicians compared with collaborative review on standardized cases.

Barnett et al., JAMA Network Open, 2019

~100

physicians have applied to work with Tachyra. A working prototype checks the full medication list, Beers Criteria, duplications, and allergens.

The offering

Seed round terms at a glance

Target raise
$6,000,000 (range $5M–$8M)
Instrument
Post-Money SAFE; valuation cap and discount set in the offering documents
Minimum investment
$25,000
Offering
Regulation D, Rule 506(c)
Eligible investors
Accredited only, with status verified before investing
Use of funds
Product and engineering, clinical validation, legal and compliance, regulatory groundwork, and the physician pilot program

See the full picture

The deck covers the market, business model, competition, financial projections, leadership team, and 24-month milestone plan.

info@tachyradiagnostics.com

A team reviewing a business presentation in a conference room

This page is for information only and is not an offer to sell or a solicitation of an offer to buy any security. Any offering will be made only through definitive offering documents under Rule 506(c) of Regulation D, and only to accredited investors whose status has been verified. The securities have not been registered under the Securities Act of 1933 or any state securities laws and are subject to restrictions on transfer. Investing in an early-stage company involves a high degree of risk, including the possible loss of the entire investment. Statements about future plans are forward-looking and may not occur.

Tachyra Diagnostics, Inc. provides AI-assisted clinical decision support software. It does not practice medicine, diagnose patients, prescribe medication, or recommend dosing. © 2026 Tachyra Diagnostics, Inc.

Scroll to Top